Patents by Inventor Dominik Haudenschild
Dominik Haudenschild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230109457Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: May 9, 2022Publication date: April 6, 2023Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Patent number: 11351161Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: April 30, 2020Date of Patent: June 7, 2022Assignee: The Regents Of The University Of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Patent number: 11020404Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: May 23, 2019Date of Patent: June 1, 2021Assignee: The Regents Of The University Of California, DavisInventors: Dominik Haudenschild, Jasper Yik
-
Publication number: 20210008054Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: April 30, 2020Publication date: January 14, 2021Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dominik HAUDENSCHILD, Paul DI CESARE, Jasper YIK, Blaine CHRISTIANSEN
-
Patent number: 10639302Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: November 20, 2018Date of Patent: May 5, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Publication number: 20200046726Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: May 23, 2019Publication date: February 13, 2020Inventors: Dominik HAUDENSCHILD, Jasper YIK
-
Publication number: 20190255034Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: November 20, 2018Publication date: August 22, 2019Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
-
Patent number: 10300073Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: October 13, 2015Date of Patent: May 28, 2019Assignee: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Jasper Yik
-
Patent number: 10172844Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: November 18, 2016Date of Patent: January 8, 2019Assignee: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Publication number: 20170304315Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: October 13, 2015Publication date: October 26, 2017Applicant: The Regents of the University of CaliforniaInventors: Dominik HAUDENSCHILD, Jasper YIK
-
Publication number: 20170246156Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: November 18, 2016Publication date: August 31, 2017Applicant: The Regents of the University of CaliforniaInventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
-
Patent number: 9498471Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: GrantFiled: October 19, 2012Date of Patent: November 22, 2016Assignee: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Patent number: 9133259Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.Type: GrantFiled: September 14, 2011Date of Patent: September 15, 2015Assignee: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
-
Publication number: 20150105423Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.Type: ApplicationFiled: October 19, 2012Publication date: April 16, 2015Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
-
Publication number: 20130315889Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.Type: ApplicationFiled: September 14, 2011Publication date: November 28, 2013Applicant: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
-
Publication number: 20040171109Abstract: This invention relates, first, to the discovery of IL-17RL, a receptor for members of the IL-17 cytokine family, particularly IL-17B. IL-17RL is naturally expressed from a 19-exon gene as a 720 amino acid protein and as any of 11 splice variants created from differential splicing of the 19 exons. The invention further relates to the discovery that IL-17B is involved in catabolic degradation of bone and cartilage and that bone and cartilage disorders can be ameliorated by pharmacological manipulation of IL-17B by antibodies or by using IL-17RL as a decoy to reduce IL-17B related catabolic activity. Methods for diagnosing cartilage disorders, and pharmaceutical compositions for slowing or ameliorating bone and cartilage pathologies are also provided.Type: ApplicationFiled: September 16, 2003Publication date: September 2, 2004Inventors: Dominik Haudenschild, Larry Rose, Timothy Moseley, A. Hari Reddi